Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Altana
Study results of anti-inflammatory agent for COPD, asthma reported
August 10th, 2005
Following the announcement of the termination of the Daxas (roflumilast) collaboration with Pfizer, Altana (ALT) reported results of the first 1-year chronic obstructive pulmonary disease (COPD) study of Daxas. The phosphodiesterase4 (PDE4)-inhibitor Daxas is an oral investigational, steroid-free anti-inflammatory agent being studied for the treatment of COPD and asthma. In the COPD study, RATIO/M2-112, the primary endpoint of lung function (FEV1) significantly improved with roflumilast treatment compared to placebo. Treatment with roflumilast was associated with 39 ± 12 ml (endpoint analysis; p=0.0005) and 48 ± 9 ml difference from...
Source: Biotech Week (2005-08-10)
|
